Literature DB >> 6138011

Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes.

G A Keepers, V J Clappison, D E Casey.   

Abstract

Initial prophylaxis with anticholinergics for neuroleptic-induced extrapyramidal syndromes (EPSs) is controversial. Recommendations, based on conflicting research findings, vary from routine prophylactic use of anticholinergics to withholding these agents until dystonia, akathisia, or parkinsonism develops. To determine whether anticholinergic prophylaxis influenced EPS rates during the first 21 days of neuroleptic treatment, 215 psychotic inpatients were reviewed. Initial prophylaxis with anticholinergic drugs significantly reduced the occurrence of EPSs. This treatment's efficacy depended on a complex interaction of variables, including the patient's sex and age, antipsychotic drug type and dose, and treatment phase.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6138011     DOI: 10.1001/archpsyc.1983.01790090075012

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  25 in total

Review 1.  Acute dystonia induced by drug treatment.

Authors:  P N van Harten; H W Hoek; R S Kahn
Journal:  BMJ       Date:  1999-09-04

Review 2.  Novel antipsychotics: issues and controversies. Typicality of atypical antipsychotics.

Authors:  E Stip
Journal:  J Psychiatry Neurosci       Date:  2000-03       Impact factor: 6.186

3.  Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial.

Authors:  Stanley N Caroff; Irene Hurford; Janice Lybrand; E Cabrina Campbell
Journal:  Neurol Clin       Date:  2011-02       Impact factor: 3.806

4.  Drug-induced parkinsonism.

Authors:  Frandy Susatia; Hubert H Fernandez
Journal:  Curr Treat Options Neurol       Date:  2009-05       Impact factor: 3.598

Review 5.  Developmental pharmacodynamics: implications for child and adolescent psychopharmacology.

Authors:  N Carrey; S Kutcher
Journal:  J Psychiatry Neurosci       Date:  1998-11       Impact factor: 6.186

6.  Relations between movement disorders and psychopathology under predominantly atypical antipsychotic treatment in adolescent patients with schizophrenia.

Authors:  Stefan Gebhardt; Fabian Härtling; Markus Hanke; Frank M Theisen; Richard von Georgi; Phillip Grant; Markus Mittendorf; Matthias Martin; Christian Fleischhaker; Eberhard Schulz; Helmut Remschmidt
Journal:  Eur Child Adolesc Psychiatry       Date:  2007-09-14       Impact factor: 4.785

7.  Extrapyramidal side effects of clozapine and haloperidol.

Authors:  M Kurz; M Hummer; H Oberbauer; W W Fleischhacker
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

Review 8.  Current Methods for the Treatment and Prevention of Drug-Induced Parkinsonism and Tardive Dyskinesia in the Elderly.

Authors:  Carlos Estevez-Fraga; Paul Zeun; Jose Luis López-Sendón Moreno
Journal:  Drugs Aging       Date:  2018-11       Impact factor: 3.923

9.  Olanzapine approved for the acute treatment of schizophrenia or manic/mixed episodes associated with bipolar I disorder in adolescent patients.

Authors:  Ann E Maloney; Linmarie Sikich
Journal:  Neuropsychiatr Dis Treat       Date:  2010-11-10       Impact factor: 2.570

10.  Use of methylphenidate in the treatment of children with autistic disorder.

Authors:  H Quintana; B Birmaher; D Stedge; S Lennon; J Freed; J Bridge; L Greenhill
Journal:  J Autism Dev Disord       Date:  1995-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.